Literature DB >> 10880413

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

A Festa1, R D'Agostino, G Howard, L Mykkänen, R P Tracy, S M Haffner.   

Abstract

BACKGROUND: Inflammation has been suggested as a risk factor for the development of atherosclerosis. Recently, some components of the insulin resistance syndrome (IRS) have been related to inflammatory markers. We hypothesized that insulin insensitivity, as directly measured, may be associated with inflammation in nondiabetic subjects. METHODS AND
RESULTS: We studied the relation of C-reactive protein (CRP), fibrinogen, and white cell count to components of IRS in the nondiabetic population of the Insulin Resistance Atherosclerosis Study (IRAS) (n=1008; age, 40 to 69 years; 33% with impaired glucose tolerance), a multicenter, population-based study. None of the subjects had clinical coronary artery disease. Insulin sensitivity (S(I)) was measured by a frequently sampled intravenous glucose tolerance test, and CRP was measured by a highly sensitive competitive immunoassay. All 3 inflammatory markers were correlated with several components of the IRS. Strong associations were found between CRP and measures of body fat (body mass index, waist circumference), S(I), and fasting insulin and proinsulin (all correlation coefficients >0.3, P<0.0001). The associations were consistent among the 3 ethnic groups of the IRAS. There was a linear increase in CRP levels with an increase in the number of metabolic disorders. Body mass index, systolic blood pressure, and S(I) were related to CRP levels in a multivariate linear regression model.
CONCLUSIONS: We suggest that chronic subclinical inflammation is part of IRS. CRP, a predictor of cardiovascular events in previous reports, was independently related to S(I). These findings suggest potential benefits of anti-inflammatory or insulin-sensitizing treatment strategies in healthy individuals with features of IRS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880413     DOI: 10.1161/01.cir.102.1.42

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  514 in total

1.  Effects of improving insulin sensitivity on nontraditional cardiovascular risk factors in patients with type 2 diabetes.

Authors:  Richard E Pratley
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 2.  Immune dysfunction and chronic inflammation following spinal cord injury.

Authors:  D J Allison; D S Ditor
Journal:  Spinal Cord       Date:  2014-11-04       Impact factor: 2.772

3.  Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse.

Authors:  Alicia H Clementi; Allison M Gaudy; Teresa A Zimmers; Leonidas G Koniaris; Robert A Mooney
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

4.  Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.

Authors:  Claude Béténé A Dooko; Stephane De Wit; Jacqueline Neuhaus; Adrian Palfreeman; Rosalie Pepe; James S Pankow; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

5.  Effects of etanercept in patients with the metabolic syndrome.

Authors:  L Elizabeth Bernstein; Jacqueline Berry; Sunnie Kim; Bridget Canavan; Steven K Grinspoon
Journal:  Arch Intern Med       Date:  2006-04-24

6.  Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.

Authors:  Paola Loria; Amedeo Lonardo; Francesca Leonardi; Cristina Fontana; Lucia Carulli; Anna Maria Verrone; Andrea Borsatti; Marco Bertolotti; Fabio Cassani; Alberto Bagni; Paolo Muratori; Dorval Ganazzi; Francesco B Bianchi; Nicola Carulli
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

Review 7.  Type 2 diabetes and risk of cognitive impairment and dementia.

Authors:  Rachel A Whitmer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 8.  Lipid abnormalities in the metabolic syndrome.

Authors:  Eliot A Brinton
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 9.  Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

Authors:  Milagros G Huerta; Jerry L Nadler
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 10.  Inflammation, insulin resistance, and obesity.

Authors:  Patrizia Ferroni; Stefani Basili; Angela Falco; Giovanni Davì
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.